Business Wire

MA-VERACODE

28.8.2024 13:51:35 CEST | Business Wire | Press release

Share
Veracode Names Co-Founder Chris Wysopal as Chief Security Evangelist and Promotes Jens Wessling to Chief Technology Officer

Veracode, a global leader in application risk management, today announced the appointments of co-founder Chris Wysopal as Chief Security Evangelist and Jens Wessling as Chief Technology Officer (CTO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828594728/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Chris Wysopal (left) named Chief Security Evangelist and Jens Wessling (right) promoted to Chief Technology Officer (Photo: Business Wire)

Brian Roche, Chief Executive Officer at Veracode, said, "Developers and security teams turn to Veracode to help them build and maintain secure software as the broad adoption of AI increases security debt and exacerbates an unmanageable security backlog. As the leader in application risk management, we have the most effective solution on the market today to secure the software supply chain. Developers face a significant challenge in finding the right security platform among a sea of options, many of which are not equal. Chris Wysopal, a pioneer in the industry, will help us cut through the noise and amplify Veracode's voice and value. Through Chris’ and Jens’ leadership, we will continue to advance our solutions, deliver innovation, educate the market, and further support our customers and partners around the globe.”

As co-founder of Veracode, Wysopal helped shape the application security testing space and will continue to educate and train the wider tech community on cybersecurity best practices. In his new role as Chief Security Evangelist, he will leverage his 25 years’ experience to influence and advocate for Veracode’s products and services, impacting customers, prospects, influencers, analysts and policy makers. As a seasoned cybersecurity expert and trusted voice in the market, he will also spend time mentoring the next generation of cybersecurity professionals.

Wysopal said, "Chief Security Evangelist is a natural evolution of my role and fulfills my passion for ensuring security is at the heart of software development, deployment and maintenance. This is a perfect fit for me as I am passionate about helping security professionals at every level solve their most pressing cybersecurity challenges. I am equally proud to hand over the CTO reigns to Jens, who has a strong track record of driving technical excellence, so Veracode can deliver even more innovation and secure the software supply chain.”

Wessling has been promoted to Chief Technology Officer after serving as Vice President and Chief Architect since he joined the company in March 2024. Wessling came to Veracode with more than 25 years’ experience in cloud computing, data engineering and software development to architect Veracode’s increasingly interconnected solutions. In his new role as CTO, he will define and shape Veracode’s global technology strategy, in addition to leading the company’s research and product security teams.

Wessling said, "I am honored to expand my leadership role at Veracode—a company that has always been at the forefront of software security. Software supply chain security is one of the biggest challenges in cybersecurity, and I look forward to contributing even more as we help organizations build, buy and implement secure software.”

To learn more, watch the interview with Chris and Jens—broadcast live on Thursday August 29, 2024, at 11.30am Eastern Time and available afterward on demand.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828594728/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye